No connection

Search Results

KPTI vs RNAC

KPTI
Karyopharm Therapeutics Inc.
BEARISH
Price
$8.00
Market Cap
$180.3M
Sector
Healthcare
AI Confidence
90%
RNAC
Cartesian Therapeutics, Inc.
BEARISH
Price
$7.04
Market Cap
$186.6M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
KPTI
--
RNAC
--
Forward P/E
KPTI
-1.83
RNAC
-4.17
P/B Ratio
KPTI
-0.5
RNAC
-1.45
P/S Ratio
KPTI
1.23
RNAC
66.72
EV/EBITDA
KPTI
-4.3
RNAC
-0.89

Profitability

Gross Margin
KPTI
9.93%
RNAC
0.0%
Operating Margin
KPTI
-52.36%
RNAC
-2316.68%
Profit Margin
KPTI
-134.21%
RNAC
0.0%
ROE
KPTI
--
RNAC
--
ROA
KPTI
-41.56%
RNAC
-14.82%

Growth

Revenue Growth
KPTI
11.6%
RNAC
--
Earnings Growth
KPTI
--
RNAC
--

Financial Health

Debt/Equity
KPTI
--
RNAC
--
Current Ratio
KPTI
1.12
RNAC
8.65
Quick Ratio
KPTI
0.98
RNAC
8.45

Dividends

Dividend Yield
KPTI
--
RNAC
--
Payout Ratio
KPTI
0.0%
RNAC
0.0%

AI Verdict

KPTI BEARISH

KPTI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -0.50, indicating negative shareholder equity. While the stock has seen a speculative 1-year price surge of 100.5%, the underlying fundamentals are catastrophic with a profit margin of -134.21% and a consistent track record of missing earnings estimates (0/4 in the last year). Despite bullish analyst targets, the combination of insider selling and extreme operational inefficiency suggests a high risk of further capital erosion.

Strengths
Positive year-over-year revenue growth of 11.60%
Recent 1-year price recovery (+100.5%)
Improving EPS growth trend (+38.1% YoY), though still deeply negative
Risks
Negative Book Value (P/B -0.50) indicating insolvency risk
Extreme operational losses (Profit Margin -134.21%)
Critical Piotroski F-Score (1/9) signaling fundamental weakness
RNAC BEARISH

RNAC exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in nearly all fundamental health categories. The company suffers from negative equity (Price/Book of -1.45) and an unsustainable operating margin of -2316.68%. While analysts maintain a 'strong_buy' rating with a target of $35.57, this is completely decoupled from the current financial reality of massive earnings misses and negative EPS growth. The combination of insider selling by the CEO and CFO and a 5-year price collapse of 93.8% suggests a high-risk speculative profile.

Strengths
Strong short-term liquidity with a Current Ratio of 8.65
High analyst conviction (Strong Buy consensus)
Recent short-term price momentum (1-week gain of 17.7%)
Risks
Negative shareholder equity (P/B -1.45)
Extreme valuation relative to sales (P/S 66.72)
Severe operational inefficiency (Operating Margin -2316.68%)

Compare Another Pair

KPTI vs RNAC: Head-to-Head Comparison

This page compares Karyopharm Therapeutics Inc. (KPTI) and Cartesian Therapeutics, Inc. (RNAC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile